Medicus Pharma CEO Dr Raza Bokhari joined Steve Darling from Proactive to announce that detailed clinical data for Teverelix, the Company’s long-acting gonadotropin-releasing hormone (GnRH) antagonist, have been accepted for e-Poster presentation at the American Association of Clinical Endocrinology (AACE) Annual Meeting, taking place April 22–24 in Las Vegas, Nevada. The acceptance represents an important milestone in advancing the clinical profile of Teverelix and increasing its visibility within the endocrinology and women’s health communities. Bokhari explained that the accepted abstract, titled “Evaluation of Teverelix,” summarizes results from two randomized, placebo-controlled Phase I clinical studies involving a total of 48 healthy premenopausal women. The studies were designed to assess the drug’s pharmacokinetics and pharmacodynamics, including how Teverelix is absorbed, its ability to suppress key reproductive hormones, its effects on bone turnover markers, and its overall safety following a single subcutaneous injection. Across both studies, participants received single doses of Teverelix at 30 mg, 45 mg, or 60 mg, or placebo, and were monitored for approximately one month. The Phase I results demonstrated rapid and reversible suppression of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), with hormone reductions observed within 24 hours of dosing. Estradiol suppression was dose-dependent and reversible, with multiple participants achieving levels within the clinically relevant Barbieri window of 30–50 pg/mL, a range associated with symptom control while reducing the risk of bone loss. The data also showed sustained pharmacodynamic activity, with hormone suppression lasting up to two to three weeks following a single injection at higher dose levels. Importantly, bone turnover markers remained stable throughout the observation period, suggesting no evidence of short-term bone loss. Teverelix was generally well tolerated, with a favorable safety profile, no drug-related serious adverse events, and only mild-to-moderate treatment-emergent adverse events reported. Bokhari also provided an update on Skinject, the company’s flagship asset targeting non-melanoma skin cancers. He confirmed a 90-patient phase two study is complete, and that Medicus Pharma is approaching a database lock and data analysis phase, with results anticipated to align with strong interim data. #proactiveinvestors #nasdaq #mdcx #tsxv #mdcx #pharma #Biotech #CancerTreatment #ClinicalTrials #FDAApproval #SkinCancer #HealthcareInnovation #Investing #MedicalResearch #SkinCancer #BasalCellCarcinoma #BiotechNews #CancerResearch #GorlinSyndrome #BasalCellCarcinoma #CompassionateUse #FDAApproval #RareDiseaseTreatment #NoninvasiveTherapy #BiotechNews